Receives Approval Notice for Drug Clinical Trial
November 14, 2025
Source: drugdu
82
Shanghai Kaibao(300039) announced on November 11 that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The drug name is KBZ24020. The approval conclusion is that the clinical trial application of KBZ24020 meets the relevant requirements for drug registration. Based on further improvement of the clinical trial protocol, the company agrees to conduct clinical trials for acute ischemic stroke.
https://finance.eastmoney.com/a/202511113561164176.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
